Logo image of ENTA

ENANTA PHARMACEUTICALS INC (ENTA) Stock Fundamental Analysis

NASDAQ:ENTA - Nasdaq - US29251M1062 - Common Stock - Currency: USD

7.51  +0.06 (+0.81%)

After market: 7.51 0 (0%)

Fundamental Rating

2

Overall ENTA gets a fundamental rating of 2 out of 10. We evaluated ENTA against 558 industry peers in the Biotechnology industry. ENTA has a bad profitability rating. Also its financial health evaluation is rather negative. ENTA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENTA had negative earnings in the past year.
In the past year ENTA has reported a negative cash flow from operations.
In the past 5 years ENTA always reported negative net income.
ENTA had negative operating cash flow in 4 of the past 5 years.
ENTA Yearly Net Income VS EBIT VS OCF VS FCFENTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

With a decent Return On Assets value of -29.85%, ENTA is doing good in the industry, outperforming 66.85% of the companies in the same industry.
ENTA has a Return On Equity (-103.08%) which is in line with its industry peers.
Industry RankSector Rank
ROA -29.85%
ROE -103.08%
ROIC N/A
ROA(3y)-30.73%
ROA(5y)-23.53%
ROE(3y)-63.25%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
ENTA Yearly ROA, ROE, ROICENTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTA Yearly Profit, Operating, Gross MarginsENTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ENTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENTA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ENTA has more shares outstanding
Compared to 1 year ago, ENTA has a worse debt to assets ratio.
ENTA Yearly Shares OutstandingENTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENTA Yearly Total Debt VS Total AssetsENTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -1.29, we must say that ENTA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.29, ENTA perfoms like the industry average, outperforming 57.17% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that ENTA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, ENTA is in line with its industry, outperforming 41.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.29
ROIC/WACCN/A
WACC14.57%
ENTA Yearly LT Debt VS Equity VS FCFENTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 5.29 indicates that ENTA has no problem at all paying its short term obligations.
ENTA's Current ratio of 5.29 is in line compared to the rest of the industry. ENTA outperforms 55.20% of its industry peers.
A Quick Ratio of 5.29 indicates that ENTA has no problem at all paying its short term obligations.
ENTA has a Quick ratio (5.29) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.29
Quick Ratio 5.29
ENTA Yearly Current Assets VS Current LiabilitesENTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.24% over the past year.
The Revenue for ENTA has decreased by -11.55% in the past year. This is quite bad
Measured over the past years, ENTA shows a very negative growth in Revenue. The Revenue has been decreasing by -19.91% on average per year.
EPS 1Y (TTM)27.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.89%
Revenue 1Y (TTM)-11.55%
Revenue growth 3Y-11.36%
Revenue growth 5Y-19.91%
Sales Q2Q%-12.48%

3.2 Future

Based on estimates for the next years, ENTA will show a decrease in Earnings Per Share. The EPS will decrease by -8.69% on average per year.
The Revenue is expected to grow by 15.91% on average over the next years. This is quite good.
EPS Next Y21.67%
EPS Next 2Y18.12%
EPS Next 3Y19.36%
EPS Next 5Y-8.69%
Revenue Next Year-11.85%
Revenue Next 2Y-5.89%
Revenue Next 3Y-4.92%
Revenue Next 5Y15.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ENTA Yearly Revenue VS EstimatesENTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M
ENTA Yearly EPS VS EstimatesENTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ENTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTA Price Earnings VS Forward Price EarningsENTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTA Per share dataENTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as ENTA's earnings are expected to grow with 19.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.12%
EPS Next 3Y19.36%

More info and screens

0

5. Dividend

5.1 Amount

ENTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENANTA PHARMACEUTICALS INC

NASDAQ:ENTA (6/26/2025, 8:00:02 PM)

After market: 7.51 0 (0%)

7.51

+0.06 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners87.38%
Inst Owner Change-2.51%
Ins Owners6.27%
Ins Owner Change3.18%
Market Cap160.56M
Analysts76.92
Price Target17.51 (133.16%)
Short Float %13.64%
Short Ratio13.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.21%
Min EPS beat(2)8.52%
Max EPS beat(2)23.9%
EPS beat(4)3
Avg EPS beat(4)11.28%
Min EPS beat(4)-14.94%
Max EPS beat(4)27.64%
EPS beat(8)5
Avg EPS beat(8)8.2%
EPS beat(12)8
Avg EPS beat(12)7.61%
EPS beat(16)10
Avg EPS beat(16)3.49%
Revenue beat(2)0
Avg Revenue beat(2)-5.94%
Min Revenue beat(2)-8.27%
Max Revenue beat(2)-3.61%
Revenue beat(4)1
Avg Revenue beat(4)-7.36%
Min Revenue beat(4)-20.14%
Max Revenue beat(4)2.56%
Revenue beat(8)4
Avg Revenue beat(8)-4.25%
Revenue beat(12)5
Avg Revenue beat(12)-5.1%
Revenue beat(16)5
Avg Revenue beat(16)-5.54%
PT rev (1m)1.98%
PT rev (3m)1.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.82%
EPS NY rev (1m)1.6%
EPS NY rev (3m)6.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.72%
Revenue NY rev (1m)1.22%
Revenue NY rev (3m)-0.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.49
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-4.54
EYN/A
EPS(NY)-3.31
Fwd EYN/A
FCF(TTM)-3.85
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS3.02
BVpS4.38
TBVpS4.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.85%
ROE -103.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.73%
ROA(5y)-23.53%
ROE(3y)-63.25%
ROE(5y)-43.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 846%
Cap/Sales 41.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.29
Quick Ratio 5.29
Altman-Z -1.29
F-Score4
WACC14.57%
ROIC/WACCN/A
Cap/Depr(3y)407.44%
Cap/Depr(5y)256.94%
Cap/Sales(3y)13.48%
Cap/Sales(5y)8.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.89%
EPS Next Y21.67%
EPS Next 2Y18.12%
EPS Next 3Y19.36%
EPS Next 5Y-8.69%
Revenue 1Y (TTM)-11.55%
Revenue growth 3Y-11.36%
Revenue growth 5Y-19.91%
Sales Q2Q%-12.48%
Revenue Next Year-11.85%
Revenue Next 2Y-5.89%
Revenue Next 3Y-4.92%
Revenue Next 5Y15.91%
EBIT growth 1Y24.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.32%
EBIT Next 3Y4.22%
EBIT Next 5YN/A
FCF growth 1Y19.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.34%
OCF growth 3YN/A
OCF growth 5YN/A